Takeaway

• In patients with advanced non-small-cell lung cancer (NSCLC), tislelizumab monotherapy as second- or third-line improved survival and response rates compared with docetaxel.
• Benefits over docetaxel were observed regardless of histology or PD-L1 expression.
• Tislelizumab showed a tolerable and manageable safety profile.

Why this matters

•  Anti-PD-1/L1 therapies have improved overall...